Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine and tamsulosin combination therapy for benign prostatic hyperplasia
ChiCTR-TRC-09000596Phase 4Completed
- Sponsor
- Peking University Shougang Hospital
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tolterodine and tamsulosin in benign prostatic hyperplasia (BPH) (4 arms), sponsored by Peking University Shougang Hospital. Primary endpoints: Maximum urinary flow rate, Average urinary flow rate and 5 more. Started Dec 2009; status: completed.
02
Drugs
tolterodinetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR-TRC-09000596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000596.